Jefferies Financial Group Inc. Takes $26.71 Million Position in Certara, Inc. $CERT

Jefferies Financial Group Inc. bought a new stake in Certara, Inc. (NASDAQ:CERT) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,031,374 shares of the company’s stock, valued at approximately $26,706,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Certara in the fourth quarter valued at about $1,322,000. Capco Asset Management LLC boosted its holdings in shares of Certara by 41.6% in the fourth quarter. Capco Asset Management LLC now owns 11,469 shares of the company’s stock valued at $101,000 after acquiring an additional 3,367 shares in the last quarter. FourThought Financial Partners LLC purchased a new stake in shares of Certara in the fourth quarter valued at about $143,000. Bastion Asset Management Inc. purchased a new stake in shares of Certara in the fourth quarter valued at about $488,000. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Certara in the fourth quarter valued at about $90,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Up 1.4%

Shares of NASDAQ CERT opened at $5.24 on Friday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $13.88. The firm has a 50-day moving average price of $5.80 and a 200 day moving average price of $7.58. The stock has a market capitalization of $815.16 million, a price-to-earnings ratio of -52.40 and a beta of 1.53.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. During the same quarter last year, the business earned $0.14 EPS. The firm’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Equities research analysts anticipate that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CERT shares. BMO Capital Markets lowered their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Robert W. Baird reduced their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Craig Hallum reduced their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Finally, Barclays reduced their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.